Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics AG (CRSP) Up 22.9% Since Last Earnings Report?

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating appeared first on Investor's Business Daily.

Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating

Fate Therapeutics

Here's what's behind two of the most exciting stocks in the gene therapy sector.

2 Top Gene Editing Stocks to Watch in June

Moderna

TG Therapeutics

By 2024, the biotech sector could rocket to $775 billion with plenty of long-term growth catalysts. And that's great news for biotech stocks.

The 3 Best Biotech Stocks to Own in 2020

Crispr Therapeutics saw its stock shoot up 15% in two days after Crispr and Vertex Pharmaceuticals gained a fast-track status for a new gene-editing drug.
The post Crispr Therapeutics Stock Jumps 15% In 2 Days After New Blood Disease Drug Fast-Tracked appeared first on Investor's Business Daily.

Crispr Therapeutics Stock Jumps 15% In 2 Days After New Blood Disease Drug Fast-Tracked

One of the company's pipeline candidates received the orphan drug designation from the FDA.

Why CRISPR Therapeutics Soared 13.8% Today

CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies

bluebird bio

Who wins in a matchup between these two gene-editing leaders?

Better Buy: Crispr Therapeutics vs. bluebird bio

Gilead Sciences

Galapagos

Incyte

Neurocrine Biosciences

Regeneron Pharmaceuticals

Acceleron Pharma

Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.

7 Beautiful Biotech Stocks to Buy Here

Global Blood Therapeutics

Novartis

Vertex Pharmaceuticals

Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.

What's The Best Biotech Stock to Buy for Treating Sickle Cell Disease?

These companies -- an online retailer and a biotech -- have plenty of growth drivers.

2 Great Stocks You Can Buy and Hold Forever: CRSP & VRTX

Exelixis

CRISPR Therapeutics and Exelixis could be excellent long-term picks for your portfolio.

Have An Extra $1,000? Buy These 2 Biotech Stocks

Adaptimmune Therapeutics

Atreca

These three clinical-stage biotechs are all bargains after last month's marketwide downturn.

Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March

Johnson & Johnson

Telesis Bio Inc

Vir Biotechnology

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

Crispr: Beyond Gene-Editing

Amgen

Biogen

Editas Medicine

Innoviva

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

7 Biotech Stocks to Buy and Hold in 2020

Intellia Therapeutics

The gene-editing revolution is already here, and could be a sizable boon for investors in three of the sector's top stocks.

The Top 3 Gene-Editing Stocks to Own in 2020

Amarin Corporation Plc

Amicus Therapeutics

Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.

With the Market Down, I'm Buying These 3 Stocks

The implications for the agricultural industry are massive.

Researchers Create New CRISPR Gene-Editing System for Plants

This gene-editing stock has been on fire throughout 2019. Will it stay that way going forward?

Can CRISPR Therapeutics Double Your Money in 2020?

ZUG, Switzerland and CAMBRIDGE, Mass., Feb.  26, 2020  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Directors at the Company’s upcoming annual general meeting to be held later this year. The Company also announced that Pablo Cagnoni, M.D., Chief Executive Officer of Rubius Therapeutics, will resign from the Board of Directors to focus on other commitments, effective immediately.

CRISPR Therapeutics Proposes Changes to the Board of Directors

These two gene-editing stocks have a lot going for them. Let's consider pipelines, partnerships, and profits to make our choice.

Better Buy:  CRISPR Therapeutics vs.  Intellia

Financial figures across the board saw significant improvements.

CRISPR Therapeutics Reports Q4 Earnings, Beats Revenue Expectations

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1175.00% and 3.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue Estimates

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Can it continue?

CRISPR Therapeutics Shows Market Leadership With Jump To 92 RS Rating

News for CRISPR Therapeutics Stock (CRSP)